Pharmaceutical News

RSS

Australian company set to spearhead drug discovery

An Australian company is set to challenge the boundaries of drug discovery in Australia with the unveiling of the nation's top drug discovery facility by Western Australian Minister for State Development, Clive Brown.

19 Apr 2004

World's largest drug-like library comprising 100 million diverse compounds synthesised in a single test tube

Nuevolution A/S, a privately held drug discovery company today announced that it has generated what it believes to be the world's largest drug-like library comprising 100 million diverse compounds synthesised in a single test tube.

19 Apr 2004

Medicare wants better access to drug discount cards

The Medicare program is taking steps to make it easier for low-income Americans to sign up for Medicare-approved prescription drug discount cards.

17 Apr 2004

Three actors tested positive for HIV - Quarantine list update

The US pornographic film industry is in turmoil from a two-month production shutdown after three actors tested positive for HIV.

17 Apr 2004

New and Generic Drug Approvals from FDA

Apidra, Diazepam Injection, Dopram, Fosamax and others

16 Apr 2004

Abbott Laboratories attempt to silence AIDS advocates

In a brazen attempt to silence AIDS advocates' ongoing criticism of Abbott Laboratories over its recent 400% price hike on the key AIDS drug Norvir, two prominent gay publications are buckling under pressure from Abbott to refuse to run, or significantly alter, a parody advertisement created by AIDS Healthcare Foundation (AHF) that spoofs the drug giant's media spin on their unprecedented price hike on Norvir.

16 Apr 2004

AIDS advocates and patients protest Abbott Laboratories' Norvir price hikes

A broad coalition of AIDS advocates and patients will come together in protest over Abbott Laboratories' recent unprecedented 400% price hike on Norvir (ritonavir), their key AIDS drug.

16 Apr 2004

GlaxoSmithKline files asthma treatment drug for approval in Japan

GlaxoSmithKline plc announced today that it has filed SeretideTM DiskusTM for approval to the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of asthma in adults and children.

16 Apr 2004

Cancer-specific protein offers new target for the development of melanoma vaccine

Scientists from the Cancer Vaccine Collaborative (CVC) have discovered that the cancer-specific protein, SSX-2, induces a spontaneous immunological reaction against cancer cells in melanoma patients, offering a new target for the development of a therapeutic melanoma vaccine. SSX-2 is the prototype of the SSX family, and is part of a larger group of proteins known as cancer/testis (CT) antigens.

16 Apr 2004

How cutting-edge computer techniques can be used to develop drugs

Leading international experts will gather at the University of Bradford's Institute for Pharmaceutical Innovation (IPI) for a conference looking at how cutting-edge computer techniques can be used to develop drugs.

16 Apr 2004

Decongestant may increase blood pressure

A common ingredient in over-the-counter decongestants -- pseudoephedrine -- may increase blood pressure and the risk of life-threatening or disabling strokes in susceptible patients, researchers at Vanderbilt University Medical Center have reported.

15 Apr 2004

HIV Vaccine Program to Lead Local Efforts

May 18 has been designated HIV Vaccine Awareness Day, a day to educate Americans about the need for a vaccine to prevent HIV. This year's theme is "Real People. Real Progress." Thousands of study volunteers, scientists, and health care professionals are committed to finding a safe and effective vaccine.

15 Apr 2004

FDA approval for skin cancer cream

3M has received an "approvable" letter from the U.S. Food and Drug Administration (FDA) in response to its supplemental new drug application on Aldara (imiquimod) Cream, 5% for the treatment of superficial basal cell carcinoma (sBCC), a common form of non-melanoma skin cancer.

14 Apr 2004

New and Generic Drug Approvals from FDA

Colgate Total Toothpaste, Heparin Sodium in 5% Dextrose Injection, Heparin Sodium in 0.9% Sodium Chloride Injection and others

14 Apr 2004

Biotech production of Sucanon Diabetes drug commences

Robert Rieveley, President of Biotech Holdings has announced that installation of pharmaceutic processing equipment required for Sucanon production is currently being completed. "Sucanon production is scheduled to begin within the week; our first production run is for 1.2 million Sucanon tablets, sufficient for 20,000 one-month Sucanon treatment packages.

14 Apr 2004

'Medicare-Approved' cards available soon

Beginning in June 2004, the Medicare discount card program will provide America's seniors and disabled Medicare beneficiaries with much-needed discounts and information on their prescription drugs. The purchasing power behind the Medicare population is expected to save beneficiaries an average of 10 to 25 percent off the retail price of most drugs.

14 Apr 2004

Canadian health groups urge ban on exportation of pharmaceutical drugs from Canada to the U.S.

Canadian health groups today called on the Government of Canada to ban the exportation of pharmaceutical drugs from Canada to the U.S. The groups, who represent the interests of millions of Canadian patients, were in Washington to highlight their concerns with Internet pharmacies.

14 Apr 2004

Drug duo prevents life-threatening condition in children undergoing stem cell transplant

A drug duo appears to be a safe and effective way to prevent a serious condition called graft-versus-host-disease (GVHD) in youngsters undergoing a stem cell transplant

14 Apr 2004

Stong evidence for lower penicillin allergic reactions

Researchers at the University of Pennsylvania School of Medicine have concluded the world's largest analysis of penicillin allergy due to re-prescription of the popular antibiotic.

14 Apr 2004

FDA approves advanced malignant melanoma drug

Maxim Pharmaceuticals today announced that its treatment protocol to provide its investigational drug Ceplene(TM), in combination with interleukin-2 (IL-2), for the treatment of patients with advanced malignant melanoma, has been approved by the U.S. Food and Drug Administration (FDA).

14 Apr 2004